Moleculin Biotech (MBRX) Receivables - Net (2018 - 2023)

Moleculin Biotech (MBRX) posted quarterly Receivables - Net of $5000.0 for Q2 2023, down 75.0% quarter-over-quarter from $20000.0 in Q4 2022.

Moleculin Biotech (MBRX) Receivables - Net (2018 - 2023) Analysis & Trends

Moleculin Biotech's Receivables - Net history runs 5 years deep, the most recent figure standing at $5000.0 for Q2 2023.

In Q2 2023, Receivables - Net changed N/A year-over-year to $5000.0; the TTM figure through Jun 2023 stood at $5000.0 (changed N/A YoY), while the FY2022 annual figure was $20000.0, changed N/A from the prior year.
Receivables - Net for Q2 2023 stood at $5000.0, down from $20000.0 in the prior quarter.
The five-year high for Receivables - Net was $316000.0 in Q3 2019, with the low at $1000.0 in Q4 2019.
The 4-year median for Receivables - Net is $5000.0 (2023), against an average of $68600.0.
Peak annual rise in Receivables - Net reached 98.21% in 2019, while the deepest fall reached 98.21% in 2019.
Moleculin Biotech's Receivables - Net stood at $1000.0 in 2019, then changed by 0.0% to $1000.0 in 2020, then jumped by 1900.0% to $20000.0 in 2022, then slumped by 75.0% to $5000.0 in 2023.
Business Quant data shows MBRX's Receivables - Net at $5000.0 in Q2 2023, $20000.0 in Q4 2022, and $1000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-
10	Moleculin Biotech	3.35 Mn	3.35 Mn	-

Download Data